Covid-19 variant symptoms 2024
Pro Research Analysisby 
Searched over 200M research papers
COVID-19 Variant Symptoms in 2024: Key Symptom Patterns
General Symptom Trends Across COVID-19 Variants
COVID-19 symptoms have changed as new variants have emerged. Early in the pandemic, loss of smell and taste were common, but these symptoms have become less frequent and less severe with newer variants, including those circulating in 2024. The 2024 strain shows reduced impact on brain regions related to smell and taste compared to the original 2020 strain, suggesting milder neurological symptoms for most people infected with recent variants.
Gastrointestinal Symptoms and Variant Differences
Gastrointestinal (GI) symptoms such as diarrhea, nausea, vomiting, abdominal pain, and loss of appetite have been reported throughout the pandemic. However, the frequency of these symptoms has declined with each new variant. For example, diarrhea was reported in 28.2% of cases early in the pandemic, but this dropped to 13.8% with the Omicron variant and has remained lower with subsequent variants. While GI symptoms are less common now, they can still complicate the illness and prolong recovery, even though they are not linked to higher mortality.
Respiratory and Pneumonia-Related Symptoms in Omicron and Recent Variants
For Omicron and its subvariants, which have dominated in 2023 and 2024, respiratory symptoms remain important. Symptoms such as dry cough, expectoration (coughing up phlegm), fever, muscle aches, sore throat, headache, shortness of breath, and difficulty breathing are associated with a higher risk of developing pneumonia. Shortness of breath and difficulty breathing, especially if symptoms last more than seven days, are strong warning signs for pneumonia in Omicron infections.
Symptom Profiles and Variant Identification
While some studies have tried to link specific symptom profiles to particular COVID-19 variants, most research does not clearly distinguish which variant is responsible for which symptoms. There is agreement that symptom severity and type can vary by variant, but more research is needed to reliably identify variants based on symptoms alone.
Vaccine Effectiveness and Symptom Reduction
Updated COVID-19 vaccines, such as the monovalent XBB.1.5 vaccine used in late 2023 and 2024, continue to provide protection against symptomatic infection from circulating Omicron lineages, including new subvariants like JN.1. Vaccination helps reduce the risk of developing symptoms and severe disease, even as the virus evolves.
Conclusion
In 2024, COVID-19 symptoms are generally milder than in earlier years, with a noticeable decline in neurological and gastrointestinal symptoms. Respiratory symptoms, especially those linked to pneumonia, remain important for monitoring disease severity. Vaccination continues to play a key role in reducing symptomatic and severe cases. While symptom patterns can hint at the circulating variant, they are not reliable for precise variant identification, and ongoing research is needed to better understand these evolving trendsAlbu2025Slabakova2023Link-Gelles2024+2 MORE.
Sources and full results
Most relevant research papers on this topic